Validating targets antiparasitic chemotherapy Alexadams freewebcam

25 Oct

If this is a republication request please include details of the new work in which the Wiley content will appear.

Received Date: October 31, 2015 Accepted Date: November 24, 2015 Published Date: November 30, 2015 Citation: Nigussie D, Beyene T, Shah NA, Belew S (2015) New Targets in Malaria Parasite Chemotherapy: A Review. doi:10.4172/2470-6965.1000S1-007 Copyright: © 2015 Nigussie D, et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Malaria Control & Elimination Malaria is a global health problem that causes significant mortality and morbidity annually and a serious problem to drug therapy and discovery as current anti-malarial therapeutics become increasingly ineffective.

Address correspondence to this author at the Drug Discovery Unit, College of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK; Tel: (44)1382 385155; Fax: (44)1382 385542; E-mail: [email protected] This is an open access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.

The discovery of drugs is a lengthy, high-risk and expensive business taking at least 12 years and is estimated to cost upwards of US0 million for each drug to be successfully approved for clinical use.

Here, we review current knowledge of neuropeptide signalling in Nematoda and Platyhelminthes, and highlight a suite of 19 protein families that yield deleterious phenotypes in helminth reverse genetics screens.

We suggest that orthologues of some of these peptidergic signalling components represent appealing therapeutic targets in parasitic helminths.• Review current knowledge of neuropeptide signalling in Nematoda and Platyhelminthes.

validating targets antiparasitic chemotherapy-35validating targets antiparasitic chemotherapy-64validating targets antiparasitic chemotherapy-6validating targets antiparasitic chemotherapy-43

Issues with current therapies include: cost; difficulties in administration; poor safety profile; and lack of efficacy e.g. In total, NTDs account for 5% of the global disease burden; yet, it is estimated only about 0.1% of global research budgets are spent on drug discovery for these diseases.

In addition, the text covers efforts towards drug development in infectious diseases from academic groups and non profit organizations.

Preamble Editor Preface PART I Drug Discovery Approaches 1 Target identification and mechanism-based screening for anthelmintics: Application of veterinary antiparasitic research programmes to search for new antiparasitic drugs for human indications 2 Anthelmintic resistance as a guide to the discovery of new drugs? Selzer studied Biology, Parasitology, and Biochemistry at the University of Tbingen, Germany, where he also received his Ph D in Biochemistry on subjects related to the protozoan parasite Trypanosoma brucei.

To ensure any drug discovery project is addressing the requirements of the patients and health care providers and delivering a benefit over existing therapies, the ideal attributes of a novel drug needs to be pre-defined by a set of criteria called a target product profile.

Using a target product profile the drug discovery process, clinical study design, and compound characteristics can be defined all the way back through to the suitability or druggability of the intended biochemical target.